Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Thomas Filleron"'
Autor:
William Jacot, Amélie Lusque, Cécile Vicier, Audrey Mailliez, Thibault de La Motte Rouge, Luc Cabel, Christelle Levy, Anne Patsouris, Isabelle Desmoulins, Lionel Uwer, Jean-Christophe Thery, Mathieu Robain, Olivier Caron, Olivier Tredan, Thomas Filleron, Jean-Sébastien Frenel, Suzette Delaloge
Publikováno v:
British Journal of Cancer. 127:1963-1973
The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively).We selected from the French
Autor:
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Hervé Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Gonçalves, Thomas Bachelot, Ivan Bieche
Publikováno v:
Nature
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Nature, 2022, 610 (7931), pp.343-348. ⟨10.1038/s41586-022-05068-3⟩
Cancer progression is driven in part by genomic alterations
Autor:
Antoine Boden, Amélie Lusque, Sabrina Lodin, Marie Bourgouin, Valérie Mauries, Christelle Moreau, Amandine Fabre, Muriel Mounier, Muriel Poublanc, Nathalie Caunes-Hilary, Thomas Filleron
Publikováno v:
BMC Cancer. 22
Background Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer. Persistent neuropathic pain, when it is ongoing and uncontrolled, has a detrimental eff
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Autor:
Nicolas Girard, Eric Pichon, David Planchard, Didier Debieuvre, Radj Gervais, Gaëlle Chenuc, Pascale Dubray-Longeras, J. Otto, Eric Dansin, Hervé Lena, Anne Madroszyk, Maurice Pérol, Thomas Filleron, Xavier Quantin, Lise Bosquet, Gaëtane Simon, Coureche Kaderbhai, Sophie Cousin, Sandrine Hiret, Christelle Clément-Duchêne, Christos Chouaid, Roland Schott
Publikováno v:
Targeted Oncology. 16:801-811
In Europe, few data regarding the characteristics of EGFR exon 20 insertion (20ins) mutations in non-small cell lung cancer (NSCLC) are available. Using a large real-world cohort, we assessed the incidence, characteristics, and outcomes of patients w
Publikováno v:
BMC Medical Research Methodology
BMC Medical Research Methodology, 2022, 22 (1), pp.278. ⟨10.1186/s12874-022-01748-w⟩
BMC Medical Research Methodology, 2022, 22 (1), pp.278. ⟨10.1186/s12874-022-01748-w⟩
Background Given the inherent challenges of conducting randomized phase III trials in older cancer patients, single-arm phase II trials which assess the feasibility of a treatment that has already been shown to be effective in a younger population ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add0126f546bd8f34a01fea210fc355d
https://www.hal.inserm.fr/inserm-04042884/file/s12874-022-01748-w.pdf
https://www.hal.inserm.fr/inserm-04042884/file/s12874-022-01748-w.pdf
Autor:
L. Digue, Marie-Noëlle Paludetto, Félicien Le Louedec, Pascale Olivier, Loic Mourey, Etienne Chatelut, Thibaud Valentin, Laurent Balardy, Thomas Filleron, Bastien Cabarrou, Carlos Gomez-Roca, Alain Ravaud
Publikováno v:
Journal of Geriatric Oncology. 12:759-764
Background Pazopanib is a tyrosine kinase inhibitor given at the approved dose of 800 mg orally once daily (OD), but often requiring individual dose adjustment due to toxicity. Limited data is available to guide prescription in older patients especia
Autor:
Anne-Cécile Brunac, Joanna Fourquet, Gaëlle Perot, Marion Jaffrelot, Julie Meilleroux, Marie Danjoux, Thomas Filleron, Vincent Nicolaï, Rosine Guimbaud, Samira Icher, Nadim Farés, Janick Selves, Frédéric Chibon
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 35(12)
The outcome of stage II-III colorectal cancer (CRC) is highly variable and therapeutic choice is currently based on TNM staging with a few additional biomarkers. However, studies show that some stage III patients have a better prognosis than some sta
Autor:
Leonor Chaltiel, Pierre Gazda, Benjamin Vairel, Thomas Filleron, Emilien Chabrillac, Agnès Dupret-Bories, Guillaume de Bonnecaze, Sébastien Vergez, Clément Gauche
Publikováno v:
European Archives of Oto-Rhino-Laryngology. 279:457-466
Transoral robotic surgery (TORS) as a first-line therapy has been well-documented but evidence is missing regarding salvage therapy. The aim of this study is to compare the oncological and functional outcomes of TORS as a primary and salvage therapy.
Autor:
Léopoldine Lapierre, Charlotte Syrykh, Laetitia Largeaud, Bastien Cabarrou, Thomas Filleron, Lucie Oberic, Salim Kanoun, Lucie Coster, Camille Laurent, Benoît Branco, Noémie Gadaud, Christian Récher, Delphine Brechemier, Laurent Balardy, François Vergez, Loïc Ysebaert, Martin Gauthier
Publikováno v:
Hematological oncologyREFERENCES. 40(4)